Cargando…
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
Prognosis for patients suffering from malignant glioma has not substantially improved. Specific immunotherapy as a novel treatment concept critically depends on target antigens, which are highly overexpressed in the majority of gliomas, but the number of such antigens is still very limited. SOX2 was...
Autores principales: | Schmitz, M, Temme, A, Senner, V, Ebner, R, Schwind, S, Stevanovic, S, Wehner, R, Schackert, G, Schackert, H K, Fussel, M, Bachmann, M, Rieber, E P, Weigle, B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360145/ https://www.ncbi.nlm.nih.gov/pubmed/17375044 http://dx.doi.org/10.1038/sj.bjc.6603696 |
Ejemplares similares
-
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
por: Schmitz, M, et al.
Publicado: (2007) -
Identification of an HLA-A(*)0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein
por: Kiessling, A, et al.
Publicado: (2004) -
NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
por: Murad, Shafiq, et al.
Publicado: (2022) -
Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer
por: Kiessling, Andrea, et al.
Publicado: (2012) -
SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells
por: Oppel, Felix, et al.
Publicado: (2011)